🔄 Niclosamide Cancer Research

Niclosamide is an FDA-approved antihelmintic medication traditionally used to treat tapeworm infections. In recent years, cancer researchers have discovered that this well-established drug may possess significant anti-cancer properties across multiple cancer types. Laboratory and preclinical studies have demonstrated that niclosamide can inhibit various cellular pathways involved in cancer growth and survival, making it an interesting candidate for cancer treatment exploration.

The growing interest in niclosamide as an off-label cancer therapy reflects a broader scientific movement toward repurposing existing medications for new therapeutic applications. This approach can accelerate drug development timelines and reduce costs compared to developing entirely new compounds. Early research suggests niclosamide may work through multiple mechanisms, including disruption of cancer cell signaling pathways and potential immune system activation. While these findings are encouraging, it is important to note that niclosamide is not an approved cancer treatment, and more clinical research is needed to establish its safety and efficacy in cancer patients.

This page provides an overview of the latest peer-reviewed research on niclosamide's potential anti-cancer activity. The articles and studies featured below represent current scientific investigations into how this medication might contribute to cancer treatment strategies. Patients and caregivers interested in exploring novel therapeutic options should discuss any potential treatments with their oncology team, as individual medical circumstances vary significantly.